Literature DB >> 3590436

[Kidney cancer with invasion of the vena cava: classification, surgical strategy and results of treatment].

G Staehler, B Liedl, E Kreuzer, W Sturm, E Schmiedt.   

Abstract

A new classification of vena caval tumor thrombi is recommended from our experience with 37 cases. For advanced tumor thrombi a surgical technique with routinely performed thoracotomy, inserting a Sarns-catheter and preparing the cardiopulmonary bypass is mandatory. If metastases are absent the prognosis of the renal carcinoma is nearly as good as in cases without tumor extension into the vena cava. The total 2-year-survival rate in our series is 47%, for the cases without metastases it is 65%. The total 5-year-survival rate is 25% and for patients without metastases 57%.

Entities:  

Mesh:

Year:  1987        PMID: 3590436

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  4 in total

1.  Successful interdisciplinary treatment of renal cell carcinoma with tumour thrombus into inferior vena cava using multimodal protocol and organ-extending R0 resection in rare horseshoe kidney and doubled right organ.

Authors:  Andreas Janitzky; Frank Meyer; Zuhir Halloul; Markus Porsch; Majed Daher; Doerthe Kuester; Maciej Pech; Uwe-Bernd Liehr
Journal:  BMJ Case Rep       Date:  2010-05-26

2.  [Renal carcinoma with invasion of the suprahepatic vena cava (Staehler stage III and IV): surgical treatment and results].

Authors:  J Roigas; A Wille; K Winter; S Deger; I Türk; R I Rückert; J Bohm; D Schnorr
Journal:  Urologe A       Date:  2003-01-30       Impact factor: 0.639

3.  Vena Cava Thrombus in Patients with Wilms Tumor.

Authors:  Clemens-Magnus Meier; Rhoikos Furtwängler; Dietrich von Schweinitz; Raimund Stein; Nils Welter; Stefan Wagenpfeil; Leo Kager; Jens-Peter Schenk; Christian Vokuhl; Patrick Melchior; Jörg Fuchs; Norbert Graf
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

Review 4.  [Surgery of inferior vena cava-associated urological tumor lesions].

Authors:  M Weber; F Meyer; U B Liehr; Z Halloul
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.